Enanta 2025 Q4 Earnings 35.7% EPS Improvement Amid Narrowed Losses

Enanta Pharmaceuticals (ENTA) reported fiscal 2025 Q4 earnings on November 19, 2025, with a 3.5% revenue increase to $15.13 million but missed revenue estimates. The stock gained 9.13% month-to-date despite a post-earnings dip.

Enanta’s Q4 results showed improved profitability, with a 35.7% reduction in per-share losses and a 35.1% narrower net loss year-over-year. While revenue fell short of expectations, cost-cutting measures and higher royalties from AbbVie’s hepatitis C treatment drove the improved financial performance.

Revenue

Enanta’s total revenue rose 3.5% to $15.13 million in Q4 2025, driven by increased royalties from AbbVie’s hepatitis C therapy, MAVYRET/MAVIRET. This marked a modest improvement from $14.61 million in the prior-year period, though it fell slightly below the $15.96 million consensus estimate.

Earnings/Net Income

The company narrowed its per-share loss to $0.87 in Q4 2025, a 35.7% improvement from $1.36 in Q4 2024. Net losses also declined by 35.1% to $18.7 million, compared to $28.8 million the previous year, reflecting reduced R&D and general administrative expenses. These improvements highlight Enanta’s progress in managing operational costs.

Post-Earnings Price Action Review

Following the earnings release, Enanta’s stock experienced mixed short-term price action. Shares dipped 1.14% on the day of the report but rebounded with a 1.68% gain during the subsequent trading week. Over the past month, the stock surged 9.13%, suggesting investor optimism about the company’s long-term prospects despite the narrowed losses. The post-earnings dip may reflect cautious sentiment around revenue shortfalls, but the broader upward trend indicates confidence in Enanta’s strategic direction.

CEO Commentary

Jay R. Luly, President and CEO of Enanta, emphasized progress across virology and immunology programs during the earnings call. He highlighted Phase 3-enabling results for zelicapavir, which demonstrated its potential to reduce RSV symptom duration. Luly also noted the selection of EPS-3903 as a lead candidate for type 2 immune diseases and the nomination of EDP-978 for KIT inhibition. The CEO expressed cautious optimism, stating that Enanta’s financial discipline and recent fundraising position the company to fund operations through fiscal 2029 while advancing its pipeline.

Guidance

Enanta expects to submit an IND for EPS-3903 in H2 2026 and for EDP-978 in Q1 2026. Management reiterated that current cash reserves, combined with retained royalties, will support operations into fiscal 2029. The company also aims to align with regulators on the registration pathway for zelicapavir in pediatric RSV patients, with topline data from the RSVHR trial anticipated in Q3 2025.

Additional News

1. Fundraising and Financial Strength: Enanta closed a $74.75 million public offering in October 2025, bolstering its cash reserves to $216.7 million as of December 31, 2024. This funding extends its operational runway to fiscal 2029.

2. Analyst Upgrades: JPMorgan initiated coverage with an Overweight rating and $17.00 price target, while Jefferies upgraded the stock to Buy with a $20.00 target, citing RSV treatment potential.

3. Clinical Advances: New data for zelicapavir and EDP-323 showed promising results in reducing RSV symptoms and viral load, with presentations at IDWeek 2025 underscoring their therapeutic potential.